Collaboration for Prevention and Treatment of MDR Bacterial Infections

Informazioni relative al progetto

COMBINE

ID dell’accordo di sovvenzione: 853967

DOI

10.3030/853967

Data della firma CE 27 Novembre 2019

Data di avvio 1 Novembre 2019

Data di completamento 30 Aprile 2027

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 25 460 100,00

Contributo UE

€ 8 000 000,00

Coordinato da

UPPSALA UNIVERSITET
Sweden

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (9)

Launch of biorepository and database

Launch of biorepository and database including five candidate bacterial reference strains, suitable for preclinical testing.

Implementation of quality standards, software and infrastructure to support data integration activities for Pillar A studies

Implementation of quality standards, software and infrastructure to support data integration activities for Pillar A studies. Documentation describing the IT solution for Pillar A related data integration.

Establish data management plan

A data management plan for COMBINE will be formulated and agreed with the partners and consortia management. The COMBINE plan will also form the basis for project data management plans within individual Pillar B and Pillar C projects and will cover GDPR, FAIR data, provenance (ALCOA) and data integration aspect.The following ethics issues to be addressed in the Data Management Plan (DMP): 1. The members of the consortium must confirm that they have appointed Data Protection Officers (DPOs) and the contact details of the DPO are made available to all data subjects involved in the research. For the members of the consortium not required to appoint a DPO under the General Data Protection Regulation a detailed data protection policy for the project must be elaborated and kept on file. It must be provided to IMI JU upon request2. A description of the technical and organisational measures that will be implemented to safeguard the rights and freedoms of the data subjects/research participants must be provided. A description of the security measures that will be implemented to prevent unauthorised access to personal data or the equipment used for processing must be provided.3. The applicants must clarify what the 'countries as yet unknown' are and what data will be imported from them to the EU. 4. For the personal data obtained from the non-EU countries the applicants must confirm that such transfers comply with the laws of the country in which the data was collected.5. Detailed information on the informed consent procedures in regard to data processing must be provided prior to the start of the relevant research activity.6. The applicants must confirm that the specific informed consent forms and information sheets for data processing (in language and terms intelligible to the participants) are kept on file. They must be provided to IMI JU upon request.7. In case of further processing of previously collected personal data, an explicit confirmation that the applicants have lawful basis for data processing and that the appropriate technical and organisational measures are in place to safeguard the rights of the data subjects must be provided. Relevant authorisations must be obtained and kept on file. The documents must be provided to IMI JU upon request.

Review of guidelines and literature around the development of monoclonal antibodies against AMR pathogens

Review of guidelines and literature around the development of monoclonal antibodies against AMR pathogens.

Review of guidelines and literature

Review of guidelines and literature on vaccines with input from expert workshop on integrated data analysis.

Implementation of quality standards, software and infrastructure to support data integration activities for data arriving from Pillar B and C projects

Implementation of quality standards, software and infrastructure to support data integration activities for data arriving from Pillar B and C projects. Documentation describing the IT solution for Pillar B and C related data integration.

Updated data management plan

Prepare an updated data management plan, taking into account the experience gained in the project implementation period.

Report on relationships between pre-clinical targets and clinical outcomes

Report on relationships between pre-clinical targets and clinical outcomes.

Charter for the Data Management Group

Document describing membership, roles, planned activities and responsibilities of the cross-accelerator DMG. All Data Management Champions will subscribe to the charter.

Websites, patent fillings, videos etc. (2)

Full set of communication material

Full set of communication material.

Project website with internal and external areas

Project website with internal and external areas.

Other (1)

Set-up of efficient meeting system across the Accelerator

Set-up of efficient meeting system across the Accelerator.

Pubblicazioni

Conference proceedings (5)

The COMBINE Pneumonia Model: Multicenter Confirmation of Virulence

Autori: Vingsbo Lundberg, Carina; Vera-Yunca, Diego; Arrazuria, Rakel; Kerscher, Bernhard; Hoover, Jennifer L.; Tassi, Natália; Sordello, Sylvie; Bekeredjian-Ding, Isabelle; Hughes, Diarmaid; Friberg, Lena E.; Hansen, Jon Ulf
Pubblicato in: 2026
Editore: AMR Conference – Novel Antimicrobials & AMR Diagnostics
DOI: 10.5281/zenodo.19604414

Development of a Murine Pneumonia Model with Methicillin-resistant Staphylococcus aureus (MRSA) to Evaluate Antibiotic Treatments

Autori: Silva Matias, Carina Sofia; Vera-Yunca, Diego; Friberg, Lena; Vingsbo Lundberg, Carina
Pubblicato in: 2025
Editore: ESCMID Conference
DOI: 10.5281/zenodo.17668732

Prediction of anti-bacterial class specificity of compounds using machine learning

Autori: Gadiya, Yojana; Zaliani, Andrea; Gribbon, Philip
Pubblicato in: Journal of Chemical Information and Modeling, 2025
Editore: American Chemical Society
DOI: 10.5281/zenodo.17650768

Exploring the Association Between Study Characteristics and Post-Vaccine Immunogenicity for C. diff: Data-Driven Analyses of Two Vaccine Trials

Autori: Stojkov, Igor; Hofner, Benjamin
Pubblicato in: 2025
Editore: AMR Conference – Novel Antimicrobials & AMR Diagnostics
DOI: 10.5281/zenodo.17661462

Tackling the Gram-Negative Permeability Barrier Through Collaborative Data-Driven Prediction

Autori: von Berlin, Leonie; Gadiya, Yojana; Fernow, Josepine; Deroose, Frederik; Gribbon, Philip
Pubblicato in: Numero 12, 2026
Editore: AMR Conference – Novel Antimicrobials & AMR Diagnostics
DOI: 10.5281/zenodo.19221951

Peer reviewed articles (6)

Challenges for Clinical Development of Vaccines for Prevention of Hospital-Acquired Bacterial Infections

Autori: Isabelle Bekeredjian-Ding
Pubblicato in: Frontiers in Immunology, Numero 11, 2020, Pagina/e (Volume 11, Article 1755), ISSN 1664-3224
Editore: Frontiers
DOI: 10.3389/fimmu.2020.01755

Expert Workshop Summary: Advancing towards a standardized murine model to evaluate treatments for AMR lung infections

Autori: Arrazuria R, Kerscher B, Huber KE, Hoover JL, Lundberg CV, Hansen JU, Sordello S, Renard S, Aranzana-Climent V, Hughes D, Gribbon P, Friberg LE, Bekeredjian-Ding I
Pubblicato in: Front Microbiol, 2022, ISSN 1664-302X
Editore: Frontiers Media
DOI: 10.3389/fmicb.2022.988725

Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant <i>Staphylococcus aureus</i>: from <i>in vitro</i> time–kill experiments to a mouse pneumonia model

Autori: Diego Vera-Yunca, Carina Matias, Carina Vingsbo Lundberg, Lena E Friberg
Pubblicato in: Journal of Antimicrobial Chemotherapy, Numero 80, 2025, Pagina/e 1860-1868, ISSN 0305-7453
Editore: Oxford University Press
DOI: 10.1093/jac/dkaf140

The COMBINE pneumonia model: a multicenter study to standardize a mouse pneumonia model with <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> for antibiotic development

Autori: Jon U. Hansen, Rakel Arrazuria, Jennifer L. Hoover, Bernhard Kerscher, Douglas L. Huseby, Sylvie Sordello, Philip Gribbon, Yojana Gadiya, Leonie von Berlin, Gesa Witt, Natália Tassi, Frederikke Rosenborg, Sha Cao, Isabelle Bekeredjian-Ding, Otto Lindahl, Diarmaid Hughes, Lena E. Friberg, Carina Vingsbo Lundberg
Pubblicato in: Microbiology Spectrum, Numero 14, 2026, ISSN 2165-0497
Editore: American Society for Microbiology
DOI: 10.1128/spectrum.03464-25

Pooled analyses of Clostridioides difficile vaccine trials identify baseline predictors for vaccine response

Autori: Igor Stojkov, Linda Marchioro, Isabelle Bekeredjian-Ding, Benjamin Hofner
Pubblicato in: Scientific Reports, Numero 16, 2026, ISSN 2045-2322
Editore: Nature Publishing Group
DOI: 10.1038/s41598-026-42375-5

Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents

Autori: Arrazuria R, Kerscher B, Huber KE, Hoover JL, Lundberg CV, Hansen JU, Sordello S, Renard S, Aranzana-Climent V, Hughes D, Gribbon P, Friberg LE, Bekeredjian-Ding I
Pubblicato in: Front Microbiol, 2022, ISSN 1664-302X
Editore: Frontiers Media
DOI: 10.3389/fmicb.2022.988728

Non-peer reviewed articles (1)

The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships

Autori: Josepine Fernow, Marie Olliver, William Couet, Sophie Lagrange, Meindert H. Lamers, Ole F. Olesen, Kristina Orrling, Michel Pieren, Derek J. Sloan, Juan José Vaquero, Timothy J. Miles, Anders Karlén
Pubblicato in: Nature Reviews Drug Discovery, 2024, ISSN 1474-1776
Editore: Nature Publishing Group
DOI: 10.1038/d41573-024-00138-9